These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39391153)

  • 1. JN.1: enhanced immune evasion ability propels it to become the predominant strain in China, unlikely to trigger pandemic similar to late 2022.
    Du P; Li M; Wei G; Guo C; Li N
    Front Public Health; 2024; 12():1442291. PubMed ID: 39391153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
    He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
    Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH
    J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.
    Jeong HW; Rollon R; Kim SM; Gil J; Casel MA; Jang H; Choi JH; Jang SG; Lazarte JC; Kim HS; Kim JH; Choi YK
    Influenza Other Respir Viruses; 2024 Oct; 18(10):e70000. PubMed ID: 39377176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
    Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
    Lancet Infect Dis; 2024 Sep; 24(9):964-973. PubMed ID: 38761806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1.
    Yang S; Yu Y; Jian F; Yisimayi A; Song W; Liu J; Wang P; Xu Y; Wang J; Niu X; Yu L; Wang Y; Shao F; Jin R; Wang Y; Cao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2343909. PubMed ID: 38616729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
    Lustig Y; Barda N; Weiss-Ottolenghi Y; Indenbaum V; Margalit I; Asraf K; Doolman R; Chalkias S; Das R; Elfatarany G; Harats D; Kreiss Y; Regev-Yochay G
    Vaccine; 2024 Sep; 42(22):126010. PubMed ID: 38806352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection.
    Liu Q; Jin M; Mei F; Fan H; Gu M; Zhang Y; Qian S; Tan X; Ji L; Zhang Z; Chen G; Yan H; Chen Y; Lan K; Geng Q; Cai K; Zhou L
    Front Cell Infect Microbiol; 2024; 14():1381877. PubMed ID: 38572316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing Infections in Two Epidemic Waves of SARS-CoV-2 Omicron Variants: A Cohort Study in Guangzhou, China.
    Qu L; Xie C; Qiu M; Yi L; Liu Z; Zou L; Hu P; Jiang H; Lian H; Yang M; Yang H; Zeng H; Chen H; Zhao J; Xiao J; He J; Yang Y; Chen L; Li B; Sun J; Lu J
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.
    Zhao XJ; Liu XL; Liang YM; Zhang S; Liu T; Li LB; Jiang WG; Chen JJ; Xu Q; Lv CL; Jiang BG; Kou ZQ; Wang GL; Fang LQ
    J Med Virol; 2024 May; 96(5):e29640. PubMed ID: 38699969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
    Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
    J Infect Dis; 2024 Aug; 230(2):e279-e286. PubMed ID: 38349280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.
    Wang Q; Mellis IA; Guo Y; Gherasim C; Valdez R; Gordon A; Ho DD; Liu L
    Cell Rep Med; 2024 Sep; 5(9):101701. PubMed ID: 39208800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.
    Yang H; Guo H; Wang A; Cao L; Fan Q; Jiang J; Wang M; Lin L; Ge X; Wang H; Zhang R; Liao M; Yan R; Ju B; Zhang Z
    Nat Commun; 2024 Sep; 15(1):7715. PubMed ID: 39231977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.
    Wang Q; Mellis IA; Ho J; Bowen A; Kowalski-Dobson T; Valdez R; Katsamba PS; Wu M; Lee C; Shapiro L; Gordon A; Guo Y; Ho DD; Liu L
    Emerg Microbes Infect; 2024 Dec; 13(1):2402880. PubMed ID: 39259045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of the First National Standard for Neutralizing Antibodies against SARS-CoV-2 XBB Variants.
    Zhang X; Guan L; Li N; Wang Y; Li L; Liu M; He Q; Lu J; Zeng H; Yu S; Guo X; Gong J; Li J; Gao F; Wu X; Chen S; Wang Q; Wang Z; Huang W; Mao Q; Liang Z; Xu M
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular epidemiology and population immunity of SARS-CoV-2 in Guangdong (2022-2023) following a pivotal shift in the pandemic.
    Li Z; Hu P; Qu L; Yang M; Qiu M; Xie C; Yang H; Cao J; Yi L; Liu Z; Zou L; Lian H; Zeng H; Xu S; Hu P; Sun J; He J; Chen L; Yang Y; Li B; Sun L; Lu J
    Nat Commun; 2024 Aug; 15(1):7033. PubMed ID: 39147778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.